Intercept Pharma is a biopharma company focused on the development of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry.

Intercept Pharma – bile acid therapeutics

One of Intercept Pharma’s candidates is Obeticholic acid (OCA), a bile acid analog. Obeticholic acid selectively binds to and activates the farnesoid X receptor (FXR) and regulates liver, intestinal, and kidney function. Intercept Pharma is developing OCA in Primary Biliary Cirrhosis (PBC) for patients with an inadequate response to standard-of-care therapy and unable to tolerate standard-of-care therapy. Primary Biliary Cirrhosis is a chronic, autoimmune, cholestatic liver disease leading to cirrhosis, liver failure, and death. Intercept owns worldwide rights to OCA outside of Japan, Korea, and China, where they have exclusively licensed the compound to Sumitomo Dainippon.

Farnesoid X receptor (FXR) Bile acid chemistry and FXR biology are at the core of Intercept’s therapeutic research. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of lipid metabolism, glucose homeostasis, etc… Intercept Pharma is pioneering the use of FXR agonism as a potential catalyst in anticholestatic and antifibrotic mechanisms

Intercept Pharma is also focusing on Nonalcoholic steatohepatitis (NASH) and Primary sclerosing cholangitis (PSC), a chronic and progressive cholestatic liver disease. Beyond obeticholic acid (OCA), Intercept is conducting further research on several innovative and promising compounds. For instance, Intercept Pharma is developing INT-767, a potentially powerful, orally administered dual farnesoid X receptor (FXR) and TGR5 agonist. Furtherore, INT-777 is an orally administered pure TGR5 agonist. In animal models of diabetes, treatment with INT-777 induced glucagon-like peptide-1 (GLP-1) secretion.

Intercept Pharma is a biopharma company headquartered in New York (USA). Management Team is composed by Mark Pruzanski, David Shapiro, Barbara Duncan, Luciano Adorini and Rachel McMinn. Board of Directors is composed by Jonathan Silverstein, Srinivas Akkaraju, Luca Benatti, Paolo Fundarò, Sanj Patel, Mark Pruzanski, Glenn Sblendorio, Klaus Veitinger and Nicole Williams.

More about Intercept Pharma : http://interceptpharma.com

Intercept Pharma – Intercept Pharmaceuticals – chronic liver diseases – bile acid – Obeticholic acid – OCA – farnesoid X receptor – FXR – INT-767 – INT-777

Intercept Pharma – chronic liver disease – Obeticholic acid – OCA – Primary Biliary Cirrhosis – PBC – farnesoid X receptor – FXR – farnesoid – cholestatic liver disease – FXR agonism – anticholestatic – antifibrotic – Nonalcoholic steatohepatitis – NASH – Primary sclerosing cholangitis – PSC – TGR5 agonist – TGR5 – glucagon-like peptide-1 – GLP-1 – Mark Pruzanski – David Shapiro – Barbara Duncan – Luciano Adorini – Rachel McMinn – Jonathan Silverstein – Srinivas Akkaraju – Luca Benatti – Paolo Fundarò – Sanj Patel – Mark Pruzanski – Glenn Sblendorio – Klaus Veitinger – Nicole Williams